Sahdev Saharan, MD
Rheumatology · Tracy, CANPI 1588875512
Payments from drug & device makers
Across 1,240 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$6K
- Johnson & Johnson$3K
- AbbVie$2K
- UCB, Inc.$2K
- GSK$2K
- AstraZeneca$1K
- plus $7K from 26 others
What the payments were for
- Food & beverage$23,48299%
- Education$3551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 353 | $6,050 |
| Johnson & Johnson(2 entities) | 155 | $2,901 |
| AbbVie | 137 | $2,334 |
| UCB, Inc. | 94 | $1,855 |
| GSK | 85 | $1,845 |
| AstraZeneca(2 entities) | 53 | $1,395 |
| Novartis | 80 | $1,290 |
| Pfizer | 51 | $1,082 |
| E.r. Squibb & Sons, L.L.C. | 43 | $832 |
| Aurinia Pharma U.S., Inc. | 29 | $668 |
| Boehringer Ingelheim | 26 | $613 |
| Genentech USA, Inc. | 26 | $600 |
| Fresenius Kabi USA, LLC | 15 | $434 |
| ANI Pharmaceuticals, Inc. | 23 | $369 |
| Mallinckrodt Hospital Products Inc. | 19 | $335 |
| Lilly USA, LLC | 13 | $284 |
| Sanofi | 8 | $186 |
| Janssen Scientific Affairs, LLC | 5 | $161 |
| Sandoz | 3 | $80 |
| Organon | 2 | $60 |
| Scilex Pharmaceuticals Inc. | 3 | $55 |
| Celltrion USA Inc. | 2 | $50 |
| Tersera Therapeutics LLC | 2 | $48 |
| Actelion Pharmaceuticals US, Inc. | 2 | $44 |
| Biocon Biologics Inc | 1 | $41 |
| Mallinckrodt Enterprises LLC | 2 | $38 |
| Hikma Pharmaceuticals USA | 2 | $38 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $37 |
| Invivyd Inc | 1 | $33 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $29 |
| Fidia Pharma USA Inc. | 1 | $27 |
| Tonix Medicines, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,837 in reported general payments places this provider in the 75th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 102 | $762,775 |
| Enbrel SureclickEtanercept | 83 | $667,460 |
| Xeljanz XrTofacitinib Citrate | 79 | $449,984 |
| OfevNintedanib Esylate | 14 | $179,887 |
| OtezlaApremilast | 34 | $167,364 |
| EnbrelEtanercept | 21 | $152,749 |
| Actemra ActpenTocilizumab | 31 | $128,179 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 18 | $124,417 |
| Cimzia (2 Pack)Certolizumab Pegol | 21 | $119,444 |
| Orencia ClickjectAbatacept | 19 | $106,401 |
| Humira PenAdalimumab | 15 | $95,656 |
| OrenciaAbatacept | 15 | $85,001 |
| RinvoqUpadacitinib | 12 | $74,034 |
| BenlystaBelimumab | 13 | $57,796 |
| Hydroxychloroquine Sulfate | 1,076 | $31,311 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla, Enbrel | $6,050 | $320,11255 claims |
| Boehringer IngelheimOfev | $613 | $179,88714 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,855 | $119,44421 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $832 | $85,00115 claims |
| AbbVieRinvoq | $2,334 | $74,03412 claims |
| GSKBenlysta | $1,845 | $57,79613 claims |
| PfizerLyrica | $1,082 | $7,09612 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $55 | $2,00335 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 808 rheumatology providers in California.
Other rheumatology in Tracy
- Samy MetyasCovina$12.9M
- Christine ThaiHuntington Beach$8.5M
- Tien-I SuWhittier$8.4M
- Eric LeeUpland$6.9M
- Orrin TroumSanta Monica$6.9M
- Shirley PangFullerton$5.7M
- William RobinsonStanford$5.1M
- Dan laTujunga$5.1M
- Christina Charles-SchoemanLos Angeles$4.8M
- Suneet GrewalWest Hollywood$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.